R P Baum

Summary

Country: Germany

Publications

  1. ncbi Evaluation of therapy response in breast and ovarian cancer patients by positron emission tomography (PET)
    R P Baum
    Zentralklinik Bad Berka Clinic of Nuclear Medicine, Center for PET, Bad Berka, Germany
    Q J Nucl Med 45:257-68. 2001
  2. ncbi Position of nuclear medicine modalities in the diagnostic workup of cancer patients: lung cancer
    R P Baum
    Department of Nuclear Medicine, Center for PET, Bad Berka, Germany
    Q J Nucl Med Mol Imaging 48:119-42. 2004
  3. ncbi FDG-PET/CT in lung cancer: an update
    Richard P Baum
    Department of Nuclear Medicine Center for PET, Zentralklinik Bad Berka, Bad Berka, Germany
    Front Radiat Ther Oncol 42:15-45. 2010
  4. ncbi Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT
    Vikas Prasad
    Department of Nuclear Medicine and Centre for PET CT, Zentralklinik Bad Berka, Robert Koch Allee 9, 99437 Bad Berka, Germany
    Eur J Nucl Med Mol Imaging 37:67-77. 2010
  5. ncbi Therapeutic nuclear medicine in pediatric malignancy
    M Schmidt
    Department of Nuclear Medicine, University of Cologne, Cologne, Germany
    Q J Nucl Med Mol Imaging 54:411-28. 2010
  6. ncbi Limited value of fluorine-18-fluorodeoxyglucose PET for the differential diagnosis of focal liver lesions in patients with chronic hepatitis C virus infection
    O Schroder
    Department of Nuclear Medicine, Johann Wolfgang Goethe University, Frankfurt Main, Germany
    Nuklearmedizin 37:279-85. 1998
  7. ncbi Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions
    V Prasad
    Department of Nuclear Medicine Center for PET, Zentralklinik Bad Berka, Bad Berka, Germany
    Q J Nucl Med Mol Imaging 54:61-7. 2010
  8. ncbi Current treatment options for neuroendocrine tumors
    D Hörsch
    Department of Gastroenterology Endocrinology, Zentralklinik Bad Berka GmbH, Bad Berka, Germany
    Drugs Today (Barc) 47:773-86. 2011
  9. ncbi A novel technetium-99m labeled monoclonal antibody (174H.64) for staging head and neck cancer by immuno-SPECT
    R P Baum
    Department of Nuclear Medicine, Johann Wolfgang Goethe-University Medical Center, Frankfurt/Main, Germany
    Acta Oncol 32:747-51. 1993
  10. ncbi [Correlation of histologic results with PET findings for tumor regression and survival in locally advanced non-small cell lung cancer after neoadjuvant treatment]
    M Schmücking
    Klinik für Nuklearmedizin PET Zentrum, Zentralklinik Bad Berka
    Pathologe 26:178-89. 2005

Collaborators

Detail Information

Publications12

  1. ncbi Evaluation of therapy response in breast and ovarian cancer patients by positron emission tomography (PET)
    R P Baum
    Zentralklinik Bad Berka Clinic of Nuclear Medicine, Center for PET, Bad Berka, Germany
    Q J Nucl Med 45:257-68. 2001
    ....
  2. ncbi Position of nuclear medicine modalities in the diagnostic workup of cancer patients: lung cancer
    R P Baum
    Department of Nuclear Medicine, Center for PET, Bad Berka, Germany
    Q J Nucl Med Mol Imaging 48:119-42. 2004
    ..The time has come for FDG-PET to find its place in new guidelines for the workup of lung cancer patients...
  3. ncbi FDG-PET/CT in lung cancer: an update
    Richard P Baum
    Department of Nuclear Medicine Center for PET, Zentralklinik Bad Berka, Bad Berka, Germany
    Front Radiat Ther Oncol 42:15-45. 2010
    ..The aim of this article is to present a concise summary of the present status of FDG-PET/CT...
  4. ncbi Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT
    Vikas Prasad
    Department of Nuclear Medicine and Centre for PET CT, Zentralklinik Bad Berka, Robert Koch Allee 9, 99437 Bad Berka, Germany
    Eur J Nucl Med Mol Imaging 37:67-77. 2010
    ....
  5. ncbi Therapeutic nuclear medicine in pediatric malignancy
    M Schmidt
    Department of Nuclear Medicine, University of Cologne, Cologne, Germany
    Q J Nucl Med Mol Imaging 54:411-28. 2010
    ..54 per 100000 per year but is the most frequent tumour of endocrine glands in children and adolescents. Management includes radioiodine therapy but there are some distinct differences in comparison to adult thyroid cancer management...
  6. ncbi Limited value of fluorine-18-fluorodeoxyglucose PET for the differential diagnosis of focal liver lesions in patients with chronic hepatitis C virus infection
    O Schroder
    Department of Nuclear Medicine, Johann Wolfgang Goethe University, Frankfurt Main, Germany
    Nuklearmedizin 37:279-85. 1998
    ..The differentiation of HCC from liver metastasis or benign disorders by imaging studies based upon morphological aspects may be difficult...
  7. ncbi Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions
    V Prasad
    Department of Nuclear Medicine Center for PET, Zentralklinik Bad Berka, Bad Berka, Germany
    Q J Nucl Med Mol Imaging 54:61-7. 2010
    ....
  8. ncbi Current treatment options for neuroendocrine tumors
    D Hörsch
    Department of Gastroenterology Endocrinology, Zentralklinik Bad Berka GmbH, Bad Berka, Germany
    Drugs Today (Barc) 47:773-86. 2011
    ..In summary, treatment options for neuroendocrine tumors have expanded considerably in the last years leading to prolonged overall survival...
  9. ncbi A novel technetium-99m labeled monoclonal antibody (174H.64) for staging head and neck cancer by immuno-SPECT
    R P Baum
    Department of Nuclear Medicine, Johann Wolfgang Goethe-University Medical Center, Frankfurt/Main, Germany
    Acta Oncol 32:747-51. 1993
    ....
  10. ncbi [Correlation of histologic results with PET findings for tumor regression and survival in locally advanced non-small cell lung cancer after neoadjuvant treatment]
    M Schmücking
    Klinik für Nuklearmedizin PET Zentrum, Zentralklinik Bad Berka
    Pathologe 26:178-89. 2005
    ..36% (p=0,0123).(18)F FDG PET precedes CT in measuring the tumor response and may predict (long term) therapeutic outcome in stage III NSCLC. Histologic regression grade correlates well with metabolic remission as detected by PET...
  11. ncbi Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?
    P Antunes
    Division of Radiological Chemistry, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland
    Eur J Nucl Med Mol Imaging 34:982-93. 2007
    ..In preclinical studies it has shown a striking superiority over its 111In-labelled congener. The purpose of this study was to evaluate whether third-generation somatostatin-based, radiogallium-labelled peptides show the same superiority...
  12. ncbi Receptor PET/CT imaging of neuroendocrine tumors
    R P Baum
    Zentralklinik Bad Berka GmbH Nuklearmedizinische Klinik, Germany
    Recent Results Cancer Res 170:225-42. 2008